Results Wire: US FDA Advisory Committee Supports a Favorable Benefit-Risk Assessment of Eli Lilly’s Necitumumab for Squamous Non-small Cell Lung Cancer – JUL 9, 2015 (ODAC)

On Thursday, July 9, 2015 the discussion among the Oncologic Drugs Advisory Committee (ODAC) supported a positive benefit-risk assessment of necitumumab injection, submitted by Eli Lilly and Company, for use in combination with gemcitabine and cisplatin, for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC).

See the SAC Tracker report